Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating […]

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025

Corsair Pharma, Inc. is a private biopharmaceutical company. The company has just announced the successful completion of a preclinical program for Its treprostinil Prodrug Transdermal System and its plans to start a Phase 1 trial in Q2 of 2025. The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025 Read Post »

TRANSLATE »
Scroll to Top